BPB Reports
Online ISSN : 2434-432X
Regular Article
Potential Ameliorative Effects of Kampo Medicines Ninjin’yoeito and Kamikihito on Frailty-Like Behavior in Naturally Aged C57BL/6J Mice
Masahiro TabuchiYosuke MatsubaraShinji MiyazakiKeita MizunoYuji OmiyaYoshiki Ikeda
著者情報
ジャーナル オープンアクセス HTML
電子付録

2022 年 5 巻 3 号 p. 59-65

詳細
抄録

Frailty is defined as an age-related decline in physiological reserve and increased vulnerability to stress. As frailty is a multifaceted condition, there is no effective pharmacotherapy for it yet. Ninjin’yoeito (NYT) and Kamikihito (KKT), traditional Japanese medicines (Kampo medicines), are promising in treating multifaceted conditions of frailty including fatigue and mental anxiety. However, their effects are still unclear. In this study, the effects of NYT and KKT on different types of frailty in naturally aged mice were explored by survival, physical aspects (Frailty Assessment Scores and muscle strength measurements), psychological aspects (sucrose splash test for motivation-related behavior), and social aspects (rescue-like behavior test for prosocial behavior). Mice aged 22-months were fed a diet containing 3% NYT or 3%KKT for 13 weeks until the age of 25 months. Behavioral alterations in old mice were compared with those in adult mice (five months old). Throughout the study period, Old-control mice showed frailty-like symptoms, including elevation of frailty assessment score, reduction of muscle strength and motivation for self-care, and rescue-like behavior compared to adult mice. NYT increased the survival rate of old mice and suppressed the declines in their frailty assessment score, muscle strength, and motivation for self-care. KKT reduced decreases in the frailty assessment score, motivation for self-care, and rescue-like behavior in old mice. These results suggest that NYT and KKT alleviate general frailty-like symptoms in old mice. Additionally, NYT may extend lifespan. These findings suggest that NYT and KKT may be helpful for improving the multifaceted symptoms of frailty.

著者関連情報
© 2022 The Pharmaceutical Society of Japan

BPB Reports applies the Creative Commons Attribution (CCBY) license to works we published. The license was developed to facilitate open access - namely, free immediate access to, and unrestricted reuse of, original works to all types. Under this license, authors agree to make articles legally available for reuse, without permissions of fees, for virtually any purpose. Anyone may copy, distribute, or reuse these articles, as long as the author and original source are properly cited.
https://creativecommons.org/licenses/by/4.0/
前の記事 次の記事
feedback
Top